DaVita enters its May 5 Q1 2026 earnings report with a notable and consistent insider-selling signal — every transaction logged over the 90-day window has been a sale, not a buy.
On March 13, multiple senior executives dumped shares at $150.72, effectively the same price at which the stock trades today. CFO Joel Ackerman cleared roughly $6.5 million across three transactions. Chief Legal Officer Kathleen Waters sold nearly $4.4 million worth. The cluster nature of the sell-off — the same date, the same price, across at least four named insiders — reads less like routine tax planning and more like coordinated pre-earnings risk management. Net insider activity across the 90-day window amounted to a positive $221 million, which reflects prior-period exercise programs rather than fresh buying; no purchase transactions appear in the recent data. The last insiders to buy were not represented in the latest filings.
Short sellers are gradually rebuilding positions heading into the report. Short Interest as a percentage of the free float has climbed roughly 7% over the past month to 8.6%. The week-on-week move was a modest reduction of 2.2%, suggesting the build has plateaued near-term rather than accelerating. Borrow remains cheap — cost to borrow is running below 0.5% — and availability is well above tight thresholds, meaning shorts face no structural squeeze pressure. Days to cover now stands above eight days on official FINRA data. The ORTEX short score has edged up to 66.6 over the last two weeks, ranking in the 94th percentile for the universe.
Options positioning tells a different story. The put/call ratio has dropped to 0.82, more than 1.5 standard deviations below its 20-day average of 0.88. Far from hedging defensively into earnings, options traders appear to be leaning toward calls — the most bullish options posture in at least the recent window, and close to the 52-week low of 0.81. That contradicts the short-seller caution signal and sets up a genuine divergence heading into the print.
The bull-bear debate on DVA revolves almost entirely around reimbursement. Berkshire Hathaway's ~45% ownership underpins the financial credibility argument, and EPS momentum scores in the 80th+ percentile suggest the company has been consistently beating estimates. On the other hand, bears point to Medicare's dominant share of revenues — roughly two-thirds of US sales — and a payer mix where commercial insurers drive most profits despite covering only 10% of patients. The most recent confirmed analyst moves, from UBS and Barclays in early February, both raised targets after the prior earnings print. UBS went to $190; Barclays moved to $158 from $143. But subsequent moves from TD Cowen and Barclays in late 2025 cut targets steadily from the mid-$160s down to $133-$149, and BofA maintained an Underperform with a $140 target as recently as September. With the stock at $151.65 and the mean target sitting near that same level, there is little consensus premium embedded in the current price. Analyst data referenced here is from early February 2026; no material moves have been reported since.
The Q1 print is therefore a test of whether DaVita's organic patient volume trends and commercial payer mix can support the EPS momentum signal — or whether the reimbursement headwinds that drove multiple target cuts throughout 2025 have persisted into the new year.
See the live data behind this article on ORTEX.
Open DVA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
